TIAP - Toronto Innovation Acceleration Partners’ Post

Kezar Life Sciences changes CEOs, lays off 41% of staff and halts preclinical R&D to extend cash runway >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #pharma #healthcare

Kezar Life Sciences changes CEOs, lays off 41% of staff and halts preclinical R&D to extend cash runway >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #pharmaceutical #biotech

AdAlta Ltd (1AD.AX:ASK) #Biotech #Healthcare 9:00am - 9:25am https://lnkd.in/eSFdFcNx • Lead asset, AD-214, a first in class molecule for $4.7 billion fibrosis market, is progressing to Phase II clinical studies with potential for valuable near term licensing transactions • New data for three partnered CAR-T discovery projects expected prior to end of 2023 • Evaluating synergistic products and technologies to expand clinical pipeline via transactions - upside potential • Completing $3.15m capital raising to generate new AD-214 clinical data and progress numerous transaction opportunities

🚀 Exciting News in Biotech Collaboration! 🧬 Thrilled to announce a strategic partnership between Claris Ventures and Evotec to accelerate programs from Claris’s portfolio into the clinic seamlessly. 🌐 Claris's portfolio, comprising nine biotech companies across Italy, Switzerland, and the UK, will now have streamlined access to Evotec’s full pre-clinical and clinical development capabilities. This collaboration builds on the success with IAMA Therapeutics, where Evotec supported their lead program IAMA-6 from pre-clinical to a successful Clinical Trial Application in December 2023. 📈 The acceleration framework agreement extends this streamlined access to all Claris's portfolio companies, providing them with Evotec’s integrated services. Evotec will continue to support the progress of these programs through a robust governance model. 🔗 Read more about our commitment to innovation and delivering impactful solutions in the press release: https://lnkd.in/eaAynVxp #Biotech #VentureCapital #Innovation #Collaboration #Biopharma #ClinicalDevelopment #Partnership

📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of March 2024 we identified the following current VC trends in Europe:   - Total Healthcare & Life Sciences funding reached EUR 1,962m - Biotech received 60% of the total investment volume (EUR 1,172m) with oncology being the leading indication (53%) - In March Tubulis GmbH (Germany) secures the highest transaction volume with EUR 128m, followed by Nouscom (Switzerland) with EUR 76m and Mission Therapeutics (United Kingdom) with EUR 51m  - M&G Investments (United Kingdom) is the most active investor (by deal volume), followed by Patient Square Capital (United States) and Rock Springs Capital (United States)   More here: https://lnkd.in/dappZ5WX

Interesting interview between Roivant CEO and BioPharma Dive.   Good discussion of M&A drivers, the obvious value of generating good clinical data for patients with unmet needs, and the capital markets. https://lnkd.in/eGD8pkdE: 2023-11-29 BioPharma Dive [issue:56859]&utm_term=BioPharma Dive #insight #biotech #capitalraising

🎁 🏆 CatSci Ltd has had many achievements over the past year with the announcements of new offerings, partnerships and more. As we are coming to the end of this series, I wanted to reflect on some of this years accomplishments that I haven’t yet mentioned. Click on the video below to check out Day 23 and 24 “Did You Know?” or read below if you missed one! Remember to check back in tomorrow for our last "Did You Know", Day 25! 🌟 Interested in learning more? Feel free to connect with me and send me a message with any questions or send me an email at [email protected]! In case you missed a fact: Day 23- CatSci won the 2023 Innovative Growth Award from the UK Fast Growth 50 Index! -> This year, our team achieved significant recognition, securing a total of 5 awards at both company and individual levels. This accomplishment reflects CatSci’s commitment to excellence. Special congratulations are extended to Sundara Lakshmi Kanniah, Mark Bate, and James Vincent for their outstanding individual achievements. Day 24-In 2023, we completed 36 projects for our customers! -> And we are just getting started! These projects were in collaboration with customers from both Large Pharma (14 projects) & Biotechs (22 projects) and ranged from early to late-stage development. With this year’s announcements of our expanded offerings, I am confident that 2024 will mark our best year yet. Let’s break down the silos in drug development together and accelerate the delivery of life-changing medicines to patients in need. #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #ChemicalDevelopment #MaterialScience #HPAPI #AnalyticalDevelopment #Oligonucleotides #MedicinesDevelopment #drugdevelopment

Flerie intends to go public 🚀 We are happy to announce an important new milestone for Flerie - Flerie Invest intends to go public via a reverse merger, and become Flerie AB (Publ). ”This broadening of our shareholder base and becoming listed is a key step in Flerie’s plan to create a new model for life science investing: We continue our long-term, active investment strategy, while offering new shareholders access to and liquidity in difficult-to-assess biotech companies. The transaction and the capital raise allow accelerated development of a risk-diversified portfolio of product development and commercial growth companies spanning obesity, diabetes, heart disease, cancer and autoimmune disorders to pharmaceutical manufacturing services, diagnostics, medical devices and tools”, comments Ted Fjällman, CEO of Flerie. Link to press release: https://lnkd.in/duwsVWmM Ted Fjällman, Mark Quick, Cecilia Schéele, Karl Elmqvist, Thomas Eldered, Michaela Gertz, Carlos V., Carl-Johan Spak, Paula Andersson, Nasdaq, #biotechinvesting

Pleased to have been selected in their highly competitive process and to participate with their excellent experienced leaders. Very exciting times for our breakthrough target reframing the knowledge around how pathological signals of any kind can gain enough influence over cellular process to a drive a normal process to overwhelm its countervailing biology, and lead to damage. Vimentin is critical to expanding their rate and efficiency, and without it, many processes wont change regardless of signal type. https://lnkd.in/g-2BagK8